Coherus BioSciences (CHRS)

Executive Summary

Coherus BioSciences is a commercial-stage biopharmaceutical company focused on biosimilars and immuno-oncology. Its marketed products, including UDENYCA (pegfilgrastim) and CYLTEZO (adalimumab), provide a foundation of recurring revenue. The company is advancing toripalimab (PD-1 inhibitor, partnered with Junshi Biosciences) for multiple cancer indications, and its pipeline includes early-stage assets like casdozokitug (IL-27 antibody) and CHS-1000 (CTLA-4). Despite recent pipeline setbacks, Coherus aims to leverage its biosimilar commercial infrastructure to drive growth and expand its oncology franchise. Near-term catalysts include potential label expansions for toripalimab and regulatory decisions on CYLTEZO interchangeability.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on CYLTEZO interchangeability designation65% success
• Q1 2027Toripalimab label expansion for additional indications (e.g., first-line non-small cell lung cancer)40% success
• Q4 2026Phase 1/2 data readout for casdozokitug in solid tumors30% success